Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

11.82 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351
Open 11.82
Bid (Size) 9.650 (100)
Ask (Size) 16.00 (500)
Prev. Close 11.82
Today's Range 11.82 - 11.82
52wk Range 5.455 - 19.11
Shares Outstanding 34,984,044
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions. 
Via The Motley Fool

Performance

YTD
-32.4%
-32.4%
1 Month
-21.6%
-21.6%
3 Month
-20.7%
-20.7%
6 Month
-15.3%
-15.3%
1 Year
+93.8%
+93.8%

More News

Read More
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report ↗
Via Chartmill
Topics Earnings
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
EyePoint (EYPT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
Via The Motley Fool
News headline image
EyePoint (EYPT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
Via MarketMinute
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
EyePoint (EYPT) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss ↗
Via Chartmill
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗
Via Benzinga
News headline image
EyePoint (EYPT) Q2 Revenue Drops 44% ↗
Via The Motley Fool

Frequently Asked Questions

Is EyePoint, Inc. - Common Stock publicly traded?
Yes, EyePoint, Inc. - Common Stock is publicly traded.
What exchange does EyePoint, Inc. - Common Stock trade on?
EyePoint, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for EyePoint, Inc. - Common Stock?
The ticker symbol for EyePoint, Inc. - Common Stock is EYPT on the Nasdaq Stock Market
What is the current price of EyePoint, Inc. - Common Stock?
The current price of EyePoint, Inc. - Common Stock is 11.82
When was EyePoint, Inc. - Common Stock last traded?
The last trade of EyePoint, Inc. - Common Stock was at 05/19/26 04:00 PM ET
What is the market capitalization of EyePoint, Inc. - Common Stock?
The market capitalization of EyePoint, Inc. - Common Stock is 413.51M
How many shares of EyePoint, Inc. - Common Stock are outstanding?
EyePoint, Inc. - Common Stock has 414M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.